Holen Sie sich die Stockscreener-App
12.28
0.16%
-0.02
Schlusskurs vom Vortag:
$12.30
Offen:
$12.33
24-Stunden-Volumen:
6,536
Relative Volume:
0.08
Marktkapitalisierung:
$872.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+8.48%
1M Leistung:
+1.57%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.97
$12.50
1-Wochen-Bereich:
$11.07
$12.50
52-Wochen-Spanne:
$7.90
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Vergleichen Sie YDES mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
12.37 | 867.41M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.51 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.20 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.28 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Yd Bio Ltd Aktie (YDES) Neueste Nachrichten
Diabetic Macular Edema Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotech - Barchart.com
YD Bio Limited Announces Directorate Changes - marketscreener.com
YDES Stock Price, News & Analysis - Stock Titan
YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations. - Research Tree
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal - Investing.com Australia
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal By Investing.com - Investing.com South Africa
How an AI cancer test in Taipei hospitals could help shape future drugs - Stock Titan
YD Bio Limited entered into a Memorandum of Understanding to acquire EG BioMed Co., Ltd. - MarketScreener
YD Bio advances cancer detection and eye disease platforms By Investing.com - Investing.com Australia
YD Bio LtdPlans to evaluate up to three acquisitions in 2026 - marketscreener.com
Yd Bio LtdPlans To Evaluate Up To Three Acquisitions In 2026 - TradingView — Track All Markets
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap - Yahoo Finance
Yd Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap - marketscreener.com
Micron and Lam Research among market cap stock movers on Tuesday By Investing.com - Investing.com India
YD Bio Limited Warrants (YDESW) Competitors - Meyka
YD Bio to establish California operations center for diagnostic development By Investing.com - Investing.com Australia
YD Bio to establish California operations center for diagnostic development - Investing.com India
YD Bio (Nasdaq: YDES) plans Calif. ops center for U.S. diagnostics - Stock Titan
Assessing YD Bio (YDES) Valuation After a Sharp One-Month Share Price Rebound - simplywall.st
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN - Finviz
YD Bio expands cancer detection platform to pancreatic and colorectal cancers - Investing.com Australia
YD Bio expands cancer detection platform to pancreatic and colorectal cancers By Investing.com - Investing.com South Africa
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection - Yahoo Finance
YD Bio (Nasdaq: YDES) widens OkaiDx to 44 states, shows 93.8% early pancreatic sensitivity - Stock Titan
YD Bio Limited (YDESW) stock historical prices and data - Yahoo Finance UK
Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday - Benzinga
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Tesla, Micron among market cap stock movers on Monday By Investing.com - Investing.com Australia
YD Bio stock rises after FDA clearance for eye care products - Investing.com Nigeria
YD Bio Stock Rises On Entry Into US Eye Care Segment - MSN
YD Bio receives FDA clearance for contact lenses and artificial tears - Investing.com India
Kyivstar Launches Starlink Direct to Cell Satellite Connectivity in Ukraine - The Manila Times
OMG Announces 28th Edition of Journal of Innovation - The Manila Times
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics - Yahoo Finance
YD Bio Limited (YDESW) Stock Historical Prices & Data - Yahoo! Finance Canada
YD Bio Limited (YDESW) company profile and facts - Yahoo Finance UK
[424B3] YD Bio Ltd Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
[6-K] YD Bio Ltd Current Report (Foreign Issuer) | YDES SEC FilingForm 6-K - Stock Titan
YD Bio Limited Announces Board and Committee Changes - MarketScreener
S&P 500, Nasdaq and Dow Jones see big rise as heavyweight tech stocks witness rebound: Check top gainers a - The Economic Times
YD Bio (NASDAQ: YDES) opens U.S. OkaiDx RUO access via CLIA/CAP lab; 95.1% accuracy - Stock Titan
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring - Yahoo Finance
YD Bio plunges 52% after InvestingPro’s overvaluation warning By Investing.com - Investing.com Australia
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES - The Manila Times
GYMD Showcases Industrial AI and Digitalization Strength at Tech Week Singapore 2025 - The Manila Times
20‑Year Exclusive Licenses — YD Bio Lists as YDES on Nasdaq to Scale cfDNA cancer tests and eye therapies - Stock Titan
YD Bio Limited (YDESW) Stock Price, News, Quote & History - Yahoo
YD Bio Ltd (YDES) latest press releases and corporate news - Yahoo
YD Bio Ltd (YDES) cash flow - Yahoo
YD Bio Ltd (YDES) Valuation Measures & Financial Statistics - Yahoo
Finanzdaten der Yd Bio Ltd-Aktie (YDES)
Es liegen keine Finanzdaten für Yd Bio Ltd (YDES) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):